[Amphastar] February 2026 Monthly Revenue NT$2.238 Billion (YoY +131.5%)
NQ Score
75/100
N1 Content Completeness
8
AI Summary (NQ-processed)
Amphastar (1795) announced astonishing financial results, with February 2026 monthly revenue soaring to NT$2.238 billion, representing a significant year-on-year increase of 131.5%. As a leading generic drug manufacturer in the Asia-Pacific region, this strong performance is likely driven by the success of high-value products such as addiction treatment drugs in overseas markets.
AI analysis data is not yet available.
Frequently Asked Questions
- Q: What was Amphastar Pharmaceuticals' revenue in February 2026?
- A: Amphastar Pharmaceuticals reported a revenue of NT$2.238 Billion in February 2026.
- Q: How did Amphastar's February 2026 revenue compare to the previous year?
- A: Amphastar's revenue in February 2026 showed a significant year-on-year increase of +131.5%.
- Q: What is the company code for Amphastar Pharmaceuticals?
- A: The company code for Amphastar Pharmaceuticals is 1795.
- Q: In which industry sector does Amphastar Pharmaceuticals operate?
- A: Amphastar Pharmaceuticals operates within the Biotechnology and Medical Industry sector.
- Q: What was the exact revenue figure in Thousand NTD for Amphastar in February 2026?
- A: The exact revenue figure for Amphastar in February 2026 was 2,238,173 Thousand NTD.